Guideline for the treatment of chronic lymphocytic leukaemia-Reference-Cited by-同舟云学术

Guideline for the treatment of chronic lymphocytic leukaemia

Published:2018-07-15 Issue:3 Volume:182 Page:344-359
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Schuh Anna H.¹,Parry-Jones Nilima²^ORCID,Appleby Niamh¹,Bloor Adrian³,Dearden Claire E.⁴,Fegan Christopher⁵^ORCID,Follows George⁶,Fox Christopher P.⁷,Iyengar Sunil⁸,Kennedy Ben⁹,McCarthy Helen¹⁰,Parry Helen M.¹¹,Patten Piers¹²,Pettitt Andrew R.¹³,Ringshausen Ingo¹⁴,Walewska Renata¹⁰,Hillmen Peter¹⁵

Affiliation:

1. NIHR BRC Oxford Molecular Diagnostic Centre; Oxford University Hospitals NHS Trust and Department of Oncology; University of Oxford; John Radcliffe Hospital; Oxford UK

2. Department of Haematology; Aneurin Bevan University Health Board; Abergavenny UK

3. Haematology; Christie Hospital; Manchester UK

4. Haematology; Royal Marsden Hospital NHS Trust; London UK

5. Cardiff & Vale University Health Board; Cardiff UK

6. Haematology; Addenbrooke's Hospital; Cambridge UK

7. Clinical Haematology; Nottingham University Hospitals NHS Trust; Nottingham UK

8. Haematology; Royal Marsden NHS Trust; Sutton UK

9. Department of Haematology; University Hospital Leicester; Leicester UK

10. Haematology; Bournemouth and Christchurch Hospitals; Bournemouth UK

11. NIHR-ACL Haematology; University of Birmingham; Birmingham UK

12. Kings College Hospital; London UK

13. Clatterbridge Cancer Centre NHS Foundation Trust; Liverpool UK

14. University of Cambridge; Cambridge UK

15. Haematology; Leeds Teaching Hospital NHS Trust; Leeds UK

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15460/fullpdf

Reference112 articles.

1. Rituximab maintenance after first-line therapy with rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) for chronic lymphocytic leukemia;Abrisqueta;Blood,2013

2. Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL;Appleby;Leukaemia & Lymphoma,2017

3. A randomized, open-label, multicentre, phase 2/3 study to evaluate the safety and efficacy of lumiliximab in combination with fludarabine, cyclophosphamide and rituximab versus fludarabine, cyclophosphamide and rituximab alone in subjects with relapsed chronic lymphocytic leukaemia;Awan;British Journal of Haematology,2014

4. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL;Badoux;Blood,2011

5. Chronic lymphocytic leukemia in the elderly: clinico-biological features, outcomes, and proposal of a prognostic model;Baumann;Haematologica,2014

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic lymphocytic leukaemia Australasian consensus practice statement;Internal Medicine Journal;2023-09

2. PI 3 Kinase, AKT , and m TOR Inhibitors;Precision Cancer Therapies, Volume 1 ‐ Targeting Oncogenic Drivers and Signaling Pathways in Lymphoid Malignancies;2023-03-15

3. Small Lymphocytic Lymphoma Masquerading as a Vallecular Mucous Retention Cyst;B-ENT;2022-10-27

4. Practical management of chronic lymphocytic leukemia with acalabrutinib;Leukemia & Lymphoma;2022-07-19

5. Guideline for the treatment of chronic lymphocytic leukaemia;British Journal of Haematology;2022-03-21